Companies / MPL

MEDIBANK PRIVATE LIMITED

ASX:MPLInsurance
2.75B shares on issueASX (delayed) · as of 28 July 2026$5.14price · delayed$14.10Bmarket cap · indicative
A
Dilution grade

No issuance filings since 2024; no dilution pressure signals in current disclosures

Cash runwayno data — not a quarterly (4C/5B) cash filer
Share-count growth (24m)0.0%no issuance filings since 2024
Raise cadence (24m)0 cash raises
Options & rights overhang0.0% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

MEDIBANK PRIVATE LIMITED has not lodged any share-issuance (Appendix 2A) filings in the disclosed window, and no new share-issuance filings have been lodged since January 2024. The company did not raise capital in the past 24 months (0 raises reported). No proposed securities issues (Appendix 3B) are pending. The company does not have a current quarterly cash report on record, so no quarterly cash balance or funding-runway figure is disclosed.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
0.0%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
—
Cash cover · not a quarterly filer

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 2.75B per ASX (delayed) (28 July 2026).
2.74B2.75B2.77BDec 24Sept 25July 26

Cash runway

Not a quarterly cash filer. This company does not lodge Appendix 4C/5B quarterly cash reports, so cash runway does not apply.

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
7 July 20263H · cancellationMPL : ORDINARY FULLY PAID2.75BAppendix 3H
7 Apr 20263H · cancellationMPL : ORDINARY FULLY PAID2.75BAppendix 3H
6 Apr 20263G · unquotedMPL : ORDINARY FULLY PAID2.75BAppendix 3G
5 Jan 20263H · cancellationMPL : ORDINARY FULLY PAID2.75BAppendix 3H
18 Dec 20253G · unquotedMPL : ORDINARY FULLY PAID2.75BAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

No options or rights over unissued shares on record.

Director dealings

DateDirectorTypeSharesOptionsValueSource
26 June 2026Michael John WilkinsOther200k——3Y notice
2 Mar 2026Jacqueline Cherie HeyBuy11k—$51k3Y notice
27 Feb 2026Peter Dobie EveringhamBuy25k—$110k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

15 July 2026Change in substantial holding
7 July 2026Notification of cessation of securities - MPL
29 June 2026Change of Director's Interest - Michael Wilkins
14 May 2026FY26 Full Year - Key Dates
4 May 2026Medibank shares business update and customer insights
30 Apr 2026Change in substantial holding
7 Apr 2026Notification of cessation of securities - MPL
6 Apr 2026Notification regarding unquoted securities - MPL
24 Mar 2026Becoming a substantial holder
20 Mar 20262022 cybercrime event - consumer class action
3 Mar 2026Change of Director's Interest - P Everingham, J Hey
1 Mar 2026Change of Director's Interest - Lisa McIntyre
23 Feb 2026Change in substantial holding
18 Feb 2026$PHY26 Results - Investor Presentation
18 Feb 2026$PHY26 Results - Media Release
18 Feb 2026Dividend/Distribution - MPL
18 Feb 2026$PHY26 Results - Appendix 4D and Financial Report
17 Feb 2026Medibank announces 2026 premium change
13 Feb 2026Re-presentation of segment results and terminology changes
5 Jan 2026Final Director's Notice - Jay Weatherill

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.